[1] |
JORDAN K, JAHN F, AAPRO M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review[J]. Ann Oncol, 2015, 26(6): 1081-1090.
doi: S0923-7534(19)31811-3
pmid: 32018835
|
[2] |
LYONS E, LINE C, LEE J J. Developing drugs for prevention of chemotherapy-induced nausea and vomiting: draft guidance from the FDA[J]. Clin Cancer Res, 2021, 27(22): 6072-6074.
doi: 10.1158/1078-0432.CCR-21-1941
|
[3] |
GRASSI L, BERARDI M A, RUFFILLI F, et al. Role of psychosocial variables on chemotherapy-induced nausea and vomiting and health-related quality of life among cancer patients: a European study[J]. Psychother Psychosom, 2015, 84(6): 339-347.
doi: 10.1159/000431256
pmid: 26402426
|
[4] |
NATALE J J. Overview of the prevention and management of CINV[J]. Am J Manag Care, 2018, 24(18 Suppl): S391-S397.
pmid: 30328690
|
[5] |
PIECHOTTA V, ADAMS A, HAQUE M, et al. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis[J]. Cochrane Database Syst Rev, 2021, 11(11): CD012775.
|
[6] |
BADARUDIN N S, MOHAMED SHAH N, MOHD KASSIM K N B, et al. A retrospective study on chemotherapy-induced nausea and vomiting in highly/moderately emetogenic chemotherapy: incidence and prescribing practice[J]. Support Care Cancer, 2022, 30(6): 5339-5349.
doi: 10.1007/s00520-022-06956-0
pmid: 35290510
|
[7] |
RAZVI Y, CHAN S, MCFARLANE T, et al. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients[J]. Support Care Cancer, 2019, 27(1): 87-95.
doi: 10.1007/s00520-018-4464-y
pmid: 30284039
|
[8] |
上海市抗癌协会癌症康复与姑息专业委员会. 化疗所致恶心呕吐全程管理上海专家共识(2018年版)[J]. 中国癌症杂志, 2018, 28(11): 946-960.
|
|
Cancer Rehabilitation and Palliative Care Committee of Shanghai Anti-Cancer Association. Shanghai Consensus Guidelines for the Management of chemotherapy-induced nausea and vomiting (2018 edition)[J]. Chin Oncol 2018, 28(11): 946-960.
|
[9] |
SUN Y, ZHENG Y Z, YANG X Y, et al. Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China[J]. J Cancer Res Clin Oncol, 2021, 147(9): 2701-2708.
doi: 10.1007/s00432-021-03554-1
pmid: 33586045
|
[10] |
COOKSLEY T, GIROTRA M, GINEX P, et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities[J]. Support Care Cancer, 2020, 28(12): 6175-6181.
doi: 10.1007/s00520-020-05709-1
|
[11] |
National Comprehensive Cancer Network. NCCN Guidelines Version 1. 2023 Antiemesis[EB/OL]. (2023-03-23)[2023-08-30]. https://www.nccn.org/guidelines.
|
[12] |
HESKETH P J, GRUNBERG S M, GRALLA R J, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group[J]. J Clin Oncol, 2003, 21: 4112-4119.
doi: 10.1200/JCO.2003.01.095
pmid: 14559886
|
[13] |
POLI-BIGELLI S, RODRIGUES-PEREIRA J, CARIDES A D, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America[J]. Cancer, 2003, 97: 3090-3098.
doi: 10.1002/cncr.v97:12
|
[14] |
BERGER M J, ETTINGER D S, ASTON J, et al. NCCN guidelines insights: antiemesis, version 2. 2017[J]. J Natl Compr Canc Netw, 2017, 15(7): 883-893.
doi: 10.6004/jnccn.2017.0117
|
[15] |
许晶, 李洁, 张美静, 等. 化疗相关性恶心呕吐的回顾性研究[J]. 临床肿瘤学杂志, 2018, 23(5): 440-443.
|
|
XU J, LI J, ZHANG M J, et al. Adherence to NCCN antiemesis guideline for chemotherapy induced nausea and vomiting: a retrospective study in changhai hospital[J]. Chin Clin Oncol, 2018, 23(5):440-443.
|
[16] |
ZHANG Y X, YANG Y P, ZHANG Z H, et al. Neurokinin-1 receptor antagonist-based triple regimens in preventing chemotherapy-induced nausea and vomiting: a network meta-analysis[J]. J Natl Cancer Inst, 2017, 109(2): djw217.
doi: 10.1093/jnci/djw217
|
[17] |
SEKINE I, SEGAWA Y, KUBOTA K, et al. Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis[J]. Cancer Sci, 2013, 104(6): 711-717.
doi: 10.1111/cas.2013.104.issue-6
|